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ABSTRACT 
Solubility is an important physicochemical factor affecting absorption of drug and its therapeutic effectiveness. In the solubility behavior of 
drugs remains one of the most exigent aspects in formulation development. Consequences of poor aqueous solubility would lead to failure in 
formulation development. Solubility enhancement leads to better absorption thus bioavailability improvement and Solid dispersions are 
investigated in many studies because they are highly versatile in their application. The poor solubility of drug substances in water and their low 
dissolution rate inaqueous G.I.T– fluid often leads to insufficient bioavailability. In the present investigation, an attempt were made to improve 
the solubility and dissolution rate of a poorly soluble drug, Azithromycin by solid dispersion method using PVP K 90 as carrier in 1:1,1:2,1:3,1:4 
and 1:5 ratios. Solid dispersion of Azithromycin was prepared by solvent evaporation method. In vitro release profiles of sol id dispersions in 
phosphate buffer pH 6.8 were comparatively evaluated and also studied against pure Azithromycin. Faster dissolution was exhibited by PVP K 
90 Solid dispersion containing 1:4 ratio. The prepared Solid dispersions were subjected for Assay, saturation solubility studies in distilled water 
and phosphate buffer pH 6.8. 
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INTRODUCTION 
Various     techniques     are     used     to     enhance     oral 
bioavailability of poorly water soluble drugs1. These 
strategies may include the use of surfactants, cyclodextrins, 
Micronization2, liquisolid techniques, Liposomes3, 
Ethosomes4, Dendrimers5,   solid   dispersions6 and   
permeation enhancersand7. 
Solid dispersions6: 
Solid dispersions are investigated in many studies because 
they are highly versatile in their application. They can form 
the basis of products applied for various routes of 
administration and for various dosage forms, including the 
most popular oral dosage form.  
Advantages of Solid Dispersions8: 
 • Solubility enhancement leads to better absorption thus 
bioavailability improvement.  
 • Better patient compliance in the form of solid dosage form. 
• Need not to conduct clinical trials as in case of chemical 
approaches i.e. Prodrug, salt formation.                                                                                                                                             
• Broad application. 
• Ease of formulation and manufacture. 
Disadvantages of Solid Dispersions: 
• During processing (mechanical stress) or storage 
(temperature and humidity stress) the amorphous state may 
undergo crystallization. 
• Moisture may increase drug mobility and promote drug 
crystallization. 
• Phase separation, crystal growth or conversion from the 
amorphous to the crystalline state or from a metastable 
crystalline form to a more stable structure during storage.  
• Poor scale-up for the purposes of manufacturing. 
Mechanisms of increased solubility due to solid 
dispersion6, 8: 
• Size reduction of drug.   
• Solubilization effect of the carrier. 
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• Improved wettability and dispersability of drug. 
• Dissolution of the drug in carrier.  
• Conversion of the drug to amorphous state.  
• Combination of any the above. 
The advantage of solid dispersion compared with 
conventional tablet/capsule formulations: 
From conventional capsules and tablets, the dissolution rate 
is limited by the size of the primary particles formed after 
the disintegration of dosage forms. In this case, an average 
particle size of 5 µm is usually the lower limit, although 
higher particle sizes are preferred for ease of handling, 
formulation, and manufacturing. On the other hand, if a solid 
dispersion or asolid solution is used, a portion of the drug 
dissolves immediately to saturate the gastrointestinal fluid, 
and the excess drug precipitates out as fine colloidal 
particles of submicron size. 
MATERIALS AND METHOD 
Materials - Azithromycin, PVP K 90, Methanol. 
Method-  
Preparation of Physical mixtures: Five physical mixtures 
(PMs) of different proportions of azithromycin with PVP K 
90 were prepared in the ratios of 1:1, 1:2, 1:3, 1:4, 1:5 w/w. 
The required amounts of azithromycin and PVP K 90 were 
weighed and mixed thoroughly by light trituration for 3 min 
in a glass mortar. The mixture was sieved and the powder 
fraction corresponding to mesh size less than 60 was 
collected for further investigation. 
Preparation of Solid dispersions6, 8, 9: 
Solvent evaporation method: 
Polymers used include: PVP K 90. Drug and carriers were 
dissolved in common solvent methanol 30 ml. Then solvent 
was evaporated under room temperature. The experiment 
was carried out in dark because drug is light sensitive. The 
resultant mixtures were powdered in mortar, sieved 
through 60 mesh sieve and stored in cap vial at room 
temperature until evaluation. 
Characterization of Solid dispersions6, 8, 10: 
Angle of Repose:   
Angle of repose has been defined as the maximum angle 
possible between the surface of pile of powder and 
horizontal plane. The angle of repose for the granules of each 
formulation was determined by the funnel method. The 
prepared granules were allowed to flow out of the funnel 
orifice fixed at a height of 2 cm from the surface on a plane 
paper kept on the horizontal platform. The gradual addition 
of the granules from the funnel mouth forms a pile of 
granules at the surface this is continued until the pile 
touches the stem tip of the funnel. A rough circle is drawn 
around the pile base and the radius of the granule cone was 
measured. Angle of repose was then calculated with the use 
of the following formula: 
Tan θ = h / r  
Where, θ= angle of repose. 
h= height of the pile. 
r = average radius of the powder cone. 
 
 
Bulk Density: 
Bulk density of the sample was determined by pouring 
gently 10g of sample through a glass funnel into a 50ml 
graduated cylinder. The volume occupied by the sample was 
recorded. The bulk density will be calculated as follows: 
Bulk Density (gm/ml) =             Weight of sample in grams 
                                                        Volume occupied by the sample 
Tapped Density: 
10 grams of sample was be poured gently through a glass 
funnel into a 50ml graduated cylinder. The cylinder will be 
tapped from height of 2 inches until a constant volume will 
be obtained. Volume occupied by the sample after tapping 
will be recorded and tapped density will be calculated as 
follows:  
Tapped Density (gm/ml) =          Weight of sample in grams 
                                                        Volume occupied by the sample 
 
Determination of Saturation Solubility: 
The shake flask method was used to determine saturation 
solubility of prepared solid dispersions in distilled water and 
phosphate buffer pH 6.8. Excess quantities of solid 
dispersions were added in 10 ml distilled water and 
phosphate buffer pH 6.8 which is then incubated in orbital 
shaker at 37˚C and at 100 rpm for 24 hrs. Solutions were 
filtered through Whatman filter paper. Absorbance of 
resulting solutions was measured on UV spectrophotometer 
at 284.80 nm and 271.5 nm in distilled water and phosphate 
buffer pH 6.8. Saturation solubility was then calculated by 
putting measured absorbance value in calibration curve 
equation for distilled water and phosphate buffer pH 6.8. 
Assay Preparation of Standard Solution: 
Azithromycin 10 mg was weighed accurately and 
transferred to 10 ml volumetric flask. It was dissolved in 
methanol and volume was made to 10 ml with phosphate 
buffer pH 6.8. From this stock solution(1000 μg/ml). 1 ml 
solution was removed and diluted to 10 ml with to get the 
solution of 10–0 μg/ml. 1 ml from this solution was taken 
and further diluted to 10 ml with phosphate buffer pH 6.8. to 
obtain the solution of final concentration 10 µg/ml. 
Absorbance of resulting solutions were measured on UV 
spectrophotometer at 271.5 nm. 
Preparation of Sample Solution:  
Solid dispersion equivalent to 10 mg azithromycin was 
weighed accurately and transferred to 10 ml volumetric 
flask.. It was dissolved in methanol and volume was made to 
10 ml with phosphate buffer pH 6.8. From this stock solution 
(1000 μg/ml). 1 ml solution was removed and diluted to 10 
ml with to get the solution of 100 μg/ml. 1 ml from this 
solution was taken and further diluted to 10 ml with 
phosphate buffer pH 6.8. to obtain the solution of final 
concentration 10 µg/ml. Absorbance of resulting solutions 
was measured on UV spectrophotometer at 271.5 nm. 
Assay was calculated by using equation:  
Sample absorbance Assay (% w/w) =   
                                                              Sample Absorbance × 100  
                                                                     Standard absorbance 
In vitro Dissolution studies of solid dispersion: In vitro 
dissolution studies were performed for solid dispersion 
using US Pharmacopoeia Dissolution Apparatus II (paddle 
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type). An accurately weighed sample of solid dispersions 
(equivalent to 30 mg azithromycin) was placed into 900 ml 
of phosphate buffer (pH 6.8), maintained at a temperature of 
37ºC ± 0.5ºC and stirred at a speed of 75 rpm. At 15 min 
time intervals, a 10 ml aliquot of the sample was withdrawn 
and the volume was replaced with an equivalent amount of 
plain dissolution medium kept at 37ºC. The collected 
samples were filtered and analyzed at λ-max 271.5 nm using 
a UV visible spectrophotometer against phosphate buffer 
(pH 6.8) taken as blank. 
RESULT AND DISCUSSION 
Evaluation of powder blend-  
Table 1: Data for evaluation of powder blend. 
Sr. No Evaluations Test RESULTS 
  SD PM 
1 Bulk Density 0.550 0.480 
2 Tapped Density 0.812 0.67 
3 Angle Of Repose 46.1 40.22 
 
Table 2: Solubility of physical mixtures in water. 
Sr.No Polymer Ratio Saturation Solubility % Increase in Solubility In Times 
1  
 
PVP K 90 
1:1 0.0413 124.45 2.24 
2 1:2 0.0233 26.63 1.26 
3 1:3 0.0336 82.60 1.82 
4 1:4 0.0473 56.03 1.52 
5 1:5 0.0281 157.06 2.57 
 
Table 3: Solubility of solid dispersion in water. 
Sr.No Polymer Ratio Saturation Solubility % Increase in Solubility In Times 
1     
 
PVP K 90 
1:1 0.0864 369.02 4.69 
2 1:2 0.043 134.23 2.34 
3 1:3 0.0895 386.81 4.86 
4 1:4 0.0910 248.91 3.48 
5 1:5 0.0642 394.56 9.94 
 
Table 4: Solubility ofphysical mixture in phosphate buffer. 
Sr.No Polymer Ratio Saturation Solubility % Increase in Solubility In Times 
1  
 
PVP K 90 
1:1 0.0464 25.40 1.25 
2 1:2 0.0726 96.21 1.96 
3 1:3 0.0538 45.40 1.45 
4 1:4 0.0737 17.02 1.77 
5 1:5 0.0433 99.18 1.99 
 
Table 5: solubility of solid dispersion in phosphate buffer. 
Sr.No Polymer Ratio Saturation Solubility % Increase in Solubility In Times 
1  
 
PVP K 90 
1:1 0.0514 38.92 1.38 
2 1:2 0.0776 109.7 2.09 
3 1:3 0.0588 58.91 1.58 
4 1:4 0.0787 30.54 1.30 
5 1:5 0.0483 112.7 2.12 
 
SDs prepared by solvent evaporation method for 1:5 ratio of 
PVP K 90showed maximum increase in Saturation solubility 
as compared to other ratios. However PVP K 90shows 
highest increase in solubility in phosphate buffer (pH 6.8). 
 
Assay: 
The drug content of prepared solid dispersions was found to 
be in the range of 99 to 102 % w/w. The drug content values 
are shown in Table. Satisfactory reproducibility of results 
were observed when assay was repeated.  
 
Table 6: Assay of solid dispersion and physical mixture. 
Sr.No Polymer Ratio % Assay 
   PM SD 
1  
PVP K 90 
1:1 100.18±0.04 101.66±0.25 
2 1:2 100.01±0.15 102.02±0.11 
3 1:3 99.95±0.22 100.02±0.18 
4 1:5 100.02±0.34 102.01±0.09 
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Figure 1: Prepared Solid dispersion 
 
Dissolution studies: 
Dissolution studies were carried out to determine the drug 
release profile from formulations and its comparison with 
that of pure drug. In vitro Dissolution studies in phosphate 
buffer pH 6.8 % Drug release for PD, PM and prepared SDs is 
shown in Table No. 7.     
 
Table 7: Cumulative Percent drug release of physical mixture in phosphate buffer pH 6.8. 
 
 
From dissolution studies, it was observed that, PD shown 22-
23% drug dissolved within 60 min. which shows strong need 
to improve the dissolution. Solid dispersions prepared by 
solvent evaporation method for all the four polymers 
showed marked increase in the dissolution profile of drug 
release as compared to PD and PM. However complexation 
with PVP K 90 showed complete drug dissolution.  
CONCLUSION 
Azithromycin is a BCS class II drug having low solubility and 
high permeability. To improve upon the dissolution 
properties, solid dispersions of azithromycin were prepared 
in different ratios with carrier PVP K 90by solvent 
evaporation method. The prepared solid dispersions were 
evaluated by saturation solubility study, dissolution studies 
and drug content. From the findings of the study conducted, 
following conclusions can be drawn: Solid dispersions 
prepared with all the carriers improved the solubility as well 
as dissolution rate of azithromycin. Solid dispersion of PVP K 
90was found to be more efficient in improving the drug 
solubility and dissolution rate.In-vitro drug release studies 
indicated complete drug release in 60 min.in as compared to 
pure drug having only 22-23% drug release in 60 min. From 
all the observation it was concluded that solid dispersion 
with PVP K 90 [1:5] by solvent evaporation method showed 
marked improvement in solubility and dissolution. Capsule 
formulation of solid dispersion also proved better 
dissolution over pure drug. 
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Time (Min) Pure Drug PVP K 90 
(1:4) 
PM SD 
15 4.02 59.98 65.25 
30 14.33 72.01 76.81 
45 16.99 91.86 98.95 
60 22.25 98.05 106.18 
